Alnylam Pharmaceuticals, Inc. vs Spotify Technology — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.83 (market cap $29.60B), while Spotify Technology trades at $484.44 (market cap $103.00B). The key difference: Spotify Technology is far larger — about 3.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Spotify Technology is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SPOT | |
|---|---|---|
Market Cap | $29.60B | $103.00B |
Sector | Health | Media |
52-Week High | $491.22 | $738.53 |
52-Week Low | $205.48 | $412.75 |
Enterprise Value | $27.56B | $92.70B |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Spotify (SPOT) trades at $489.65, down 4.33% in the last session, amid mixed technical signals and strong fundamentals. The stock shows a bullish moving average trend but neutral oscillators, with key support at $487. Financially, revenue grew to $17.19B in 2025 with a net income margin of 12.87%, while recent news highlights initiatives like AI artist labeling to enhance transparency.
Outlook remains positive with a consensus price target of $598.20, implying 22% upside, driven by subscriber growth and margin expansion. Risks include competitive pressures and cost management, but analyst sentiment is bullish with 62% buy ratings, supporting long-term value for investors.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →